Attenuation of endotoxin-induced pathophysiology by a new potent paf receptor antagonist

Shock

Volumn 5, Issue 4, 1996, Pages 265-273

  Kruse Elliott, Kris T ^a   Albert, Daniel H ^c   Summers, James B ^c   Carter, George W ^c   Zimmerman, Jerry J ^b   Grossman, Jeffrey E ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ACETOXYMETHYL 3 [7 [[1 (N,N DIMETHYLCARBAMOYL) 6 (4 FLUOROPHENYL) 3 INDOLYL]CARBONYL] 1H,3H PYRROLO[1,2 C]THIAZOL 3 YL]PYRIDINIUM CHLORIDE; ANTITHROMBOCYTIC AGENT; CELL SURFACE RECEPTOR; FIBRINOGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; LIPOPOLYSACCHARIDE; PEROXIDASE; PRODRUG; PYRIDINIUM DERIVATIVE; THIAZOLE DERIVATIVE; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; THROMBOXANE B2;

ANIMAL; ARTICLE; BLOOD; BLOOD PRESSURE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYMOLOGY; HEART OUTPUT; HEART STROKE VOLUME; LUNG; METABOLISM; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY; SEPTIC SHOCK; SWINE; VASCULAR RESISTANCE;

ANIMALS; BLOOD PRESSURE; CARDIAC OUTPUT; DOSE-RESPONSE RELATIONSHIP, DRUG; LIPOPOLYSACCHARIDES; LUNG; PEROXIDASE; PLATELET ACTIVATING FACTOR; PLATELET AGGREGATION INHIBITORS; PLATELET MEMBRANE GLYCOPROTEINS; PRODRUGS; PYRIDINIUM COMPOUNDS; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED; SHOCK, SEPTIC; STROKE VOLUME; SWINE; THIAZOLES; THROMBOXANE B2; VASCULAR RESISTANCE;

EID: 0030124560     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-199604000-00006     Document Type: Article

References (24)

1. Olson NC, Kruse-Elliott KT, Dodam JR: Systemic and pulmonary reactions in swine with endotoxemia and Gram-negative bacteremia. J Am Vet Med Assoc 200:1870-1884, 1992.
2. Olson NC: SRI 63-675: A platelet-activating factor receptor antagonist. Cardiovasc Drug Rev 10:54-70, 1992.
3. Dobrowsky RT, Voyksner RD, Olson NC: Effect of SRI 63-675 on hemodynamics and blood PAF levels during porcine endotoxemia. Am J Physiol 260:H1455-H1465, 1991.
4. Olson NC, Joyce PB, Fleisher LN: Role of platelet-activating factor and eicosanoids during endotoxin-induced lung injury in pigs. Am J Physiol 258:H1674-H1686, 1990.
5. Sessler CN, Glauser FL, Davis D, Fowler AA III: Effects of platelet-activating factor antagonist SRI 63-441 on endotoxemia in sheep. J Appl Physiol 65:2624-2631, 1988.
6. Byrne K, Sessler CN, Carey PD, et al: Platelet-activating factor in porcine Pseudomonas acute lung injury. J Surg Res 50:111-118, 1991.
7. Mozes T, Heiligers JPC, Tak CJAM, et al: Platelet-activating factor is one of the mediators involved in endotoxic shock in pigs. J Lipid Mediators 4:309-326, 1991.
8. Chang S-W: Endotoxin-induced pulmonary leukostasis in the rat: Role of platelet-activating factor and tumor necrosis factor. J Lab Clin Med 123:65-72, 1994.
9. Kurose I, Granger DN: PAF in ischemia and reperfusion: Effects on the microvasculature. J Lipid Med Cell Signal 10:98-91, 1994.
10. Olson NC, Kruse-Elliott KT, Johnson LW: Effect of 5-lipoxygenase and cyclooxygenase blockade on porcine hemodynamics during continuous infusion of platelet-activating factor. Prostaglandins Leukotrienes Essent Fatty Acids 49:549-559, 1993.
11. Abu-Zidan FM, Walther S, Lennquist S: Modulation of lung injury by platelet-activating factor antagonism in nonhypotensive porcine endotoxemia. Circ Shock 44:148-153, 1995.
12. Baum TD, Heard SO, Latka CA, Fink MP: Endotoxin-induced myocardial depression in rats: Effect of ibuprofen and SDZ 64-688, a platelet-activating factor receptor antagonist. J Surg Res 48:629-634, 1994.
13. Chang S-W, Fedderesen CO, Henson PM, Voelkel NF: Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J Clin Invest 79:1498-1509, 1987.
14. Chang S-W, Fernyak S, Voelkel NF: Beneficial effect of a platelet-activating factor antagonist, WEB 2086, on endotoxin-induced lung injury. Am J Physiol 258:H153-H158, 1990.
15. Dirkes K, Harris BH, Connolly RJ, Schwaitzberg SD, Dinarello CA, Gelfand JA: Platelet-activating factor-antagonist improves survival in experimental Staphylococcal septicemia. J Pediatr Surg 29:1055-1058, 1994.
16. Herbertson MJ, Werner HA, Walley KR: Platelet-activating factor antagonism improves cardiopulmonary function during endotoxemia. Am J Respir Crit Care Med 151:A447, 1995.
17. Kawamura M, Kitayoshi T, Terashita Z, Fujiwara S, Takatani M, Nishikawa K: Effects of TCV-309, a novel PAF antagonist, on circulatory shock and hematological abnormality induced by endotoxin in dogs. J Lipid Med Cell Signal 9:255-265, 1994.
18. Yue T-L, Farhat M, Rabinovici R, Perera PY, Vogel SN, Feuerstein G: Protective effect of BN50739, a new platelet-activating factor antagonist, in endotoxin-treated rabbits. J Pharmacol Exp Ther 254:976-981, 1990.
19. Dhainaut J-FA, Tenaillon A, Tulzo YL, et al: Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 22:1720-1728, 1994.
20. Canale P, Squadrito F, Altavilla D, et al: TCV-309, a novel platelet-activating factor antagonist, inhibits leukocyte accumulation and protects against splanchnic artery occlusion shock. Agents Actions 42:128-134, 1994.
21. Kruse-Elliott KT, Dodam JR, Johnson LW, Olson NC: Differential effects of WEB 2086 and SRI 63-441 on TNFα-induced alterations in cardiopulmonary function. Am J Physiol 263:H761-H770, 1992.
22. Davidsen SK, Summers JB, Albert DH, et al: N-(acyloxyalkyl)pyridinium salts as soluble prodrugs of a potent platelet-activating factor antagonist. J Med Chem 37:4423-4429, 1994.
23. Goldblum SE, Wu K, Jay M: Lung myeloperoxidase as a measure of pulmonary leukostasis in rabbits. J Appl Physiol 59:1978-1985, 1985.
24. Steel RGG, Torrie JH: Principles and Procedures of Statistics: A Biometrical Approach, 2nd ed. New York: McGraw Hill Book Co., 1980, pp 137-233.